Cadila Healthcare Ltd has received approval from the US Food and Drug Administration
for marketing hydroxychloroquine sulphate tablets in the strength of 200 mg.
company will market the drug through its US subsidiary, Zydus Pharmaceuticals
(USA) Inc, the company said in a statement.
The drug falls in the disease
modifying anti-rheumatic drug (DMARD) segment and is used in the management of
sales of such tablets in the US market in 2006 as per NDC Health stood at an estimated